RCAMU
PTCT icon

Rothschild & Co Asset Management US’s PTC Therapeutics PTCT Stock Holding History

Rothschild & Co Asset Management US’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-136,604
Closed -$8.34M – 293
2020
Q4 		$8.34M Buy
136,604
+2,165
+2% +$128K 0.11% 206
2020
Q3 		$6.29M Buy
134,439
+4,652
+4% +$229K 0.11% 224
2020
Q2 		$6.58M Buy
129,787
+1,793
+1% +$88.1K 0.1% 247
2020
Q1 		$5.71M Buy
127,994
+109,701
+600% +$5.52M 0.09% 247
2019
Q4 		$879K Sell
18,293
-847
-4% -$36K 0.01% 324
2019
Q3 		$647K Buy
19,140
+2,043
+12% +$88.9K 0.01% 328
2019
Q2 		$769K Sell
17,097
-228
-1% -$9K 0.01% 326
2019
Q1 		$652K Sell
17,325
-14,367
-45% -$482K 0.01% 345
2018
Q4 		$1.09M Buy
31,692
+3,439
+12% +$124K 0.01% 348
2018
Q3 		$1.33M Buy
+28,253
New +$1.17M 0.01% 347

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Rothschild & Co Asset Management US's PTCT Position: Q1 2021 in Review

Rothschild & Co Asset Management US sold out of PTC Therapeutics (PTCT) in Q1 2021, closing a stake of 136,604 shares — an estimated $8.34M sold.

Rothschild & Co Asset Management US first reported a position in PTCT in Q3 2018 and held it in 10 quarters. The position peaked at $8.34M in Q4 2020. 207 funds tracked by Wall St. Rank hold PTCT as of Q1 2021.

  • Rothschild & Co Asset Management US reported no remaining PTC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 136,604 PTC Therapeutics shares in Q1 2021, an estimated $8.34M.
  • Rothschild & Co Asset Management US first reported a position in PTC Therapeutics in Q3 2018 and held it in 10 quarters.
  • Rothschild & Co Asset Management US's PTC Therapeutics position peaked at $8.34M in Q4 2020.
  • 207 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2021.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2021, filed 14 May 2021.